Effects of Compound Probiotics-Polygonatum Sibiricum on Liver Health and Metabolism in Middle-aged and Elderly People

Launched by WECARE PROBIOTICS CO., LTD. · Mar 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a special blend of probiotics, called Huangqian-biobacteria, on liver health and metabolism in middle-aged and older adults who have fatty liver. The goal is to see if this probiotic preparation can improve liver function, metabolism, and related health markers over a 3-month period. Researchers will also monitor for any side effects that participants might experience during the study.

To participate, individuals must be between 40 and 80 years old and have certain health issues related to metabolism, such as fatty liver, high blood pressure, prediabetes, or being overweight. However, people with specific health conditions, such as severe liver or kidney disease, recent serious gastrointestinal problems, or those who are pregnant or breastfeeding, will not be eligible. If you or a loved one meet these criteria and are interested, this trial could offer a chance to explore a potential new treatment for liver health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The age of the subjects is 40-80 years old; 2. The subject meets one of the following metabolic disease components: ① abdominal B - ultrasound shows fatty liver or fat infiltration; ② arterial blood pressure is higher than 130/85mmHg, or the subject is on antihypertensive treatment; ③ prediabetes or type 2 diabetes, with fasting blood glucose above 6.1mmol/L; ④ overweight or obesity, with BMI of 24.0kg/m² or more, or male waist circumference of 90cm or more, female waist circumference of 85cm or more, or excessive body fat content and percentage.
• • -
• Exclusion Criteria:
• • 1. People who are allergic to any of the pharmaceutical ingredients used in this study; A history of alcohol abuse (drinking more than 14 units of alcohol per week :1 unit = 285mL for beer, 25mL for spirits, 100mL for wine);
• • 2. Patients who received probiotics within 1 month before taking the experimental drug;
• • 3. Recent history of gastrointestinal bleeding, obstruction, perforation, tumor and other serious organic diseases;
• • 4. Aminotransferase index \> 3 times the normal value;
• • 5. Kidney disease (creatinine index higher than normal);
• • 6. Patients with serious psychological and mental diseases, resulting in the inability to express themselves normally;
• • 7. Patients with infectious liver diseases, such as hepatitis B and C;
• • 8. The female subject is breastfeeding or has a positive pregnancy test result during the screening period or during the test -